Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

101
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
101
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Management of Insomnia01:19

Management of Insomnia

234
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
234
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

154
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
154

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns, Predictors, and Correlates of Problematic Alcohol Use and Remission From Adolescence to Early Midlife.

Alcohol, clinical & experimental research·2026
Same author

Relationship between new-onset falls and neuroimaging markers of Alzheimer's disease in the UK Biobank.

Journal of Alzheimer's disease : JAD·2026
Same author

Tracking the longitudinal course of physiologic and mental health functioning among individuals in substance use disorder treatment.

Frontiers in psychiatry·2026
Same author

Tau burden across Braak stages is associated with regionally specific amyloid accumulation.

Brain communications·2026
Same author

APOE ε4 and amyloid status moderate the associations between sleep, physical activity, and tau-PET burden in cognitively unimpaired older adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Diffusion Tensor Imaging Correlates of Financial Capacity Instrument-Short Form Completion Time in Mild Cognitive Impairment.

The Journal of neuropsychiatry and clinical neurosciences·2026

Related Experiment Video

Updated: Jun 10, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

608

A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone

Estelle Eyob1, Jacob S Shaw1, Arnold Bakker1

  • 1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Journal of Alzheimer'S Disease : JAD
|October 18, 2024
PubMed
Summary

Investigating trazodone for Alzheimer's disease (AD) in older adults with mild cognitive impairment (MCI) and sleep issues. This study aims to improve slow wave sleep and slow cognitive decline.

Keywords:
Alzheimer’s diseasecircadian rhythmshippocampusmild cognitive impairmentsleeptrazodone

More Related Videos

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory
08:08

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory

Published on: June 18, 2014

27.0K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.3K

Related Experiment Videos

Last Updated: Jun 10, 2025

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

608
Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory
08:08

Eye Tracking, Cortisol, and a Sleep vs. Wake Consolidation Delay: Combining Methods to Uncover an Interactive Effect of Sleep and Cortisol on Memory

Published on: June 18, 2014

27.0K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.3K

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a major cause of death and disability in aging populations, with limited treatment options.
  • Sleep disturbances are a significant risk factor for AD, potentially due to impaired protein aggregate clearance and altered neural activity.
  • Slow wave sleep is crucial for neuroprotection, and targeting sleep in early AD stages (mild cognitive impairment - MCI) may slow cognitive decline.

Purpose of the Study:

  • To investigate the effects of trazodone on sleep and cognition in older adults with amnestic MCI and sleep complaints.
  • To evaluate trazodone's potential to improve slow wave sleep, a critical phase for neuroprotection.
  • To assess trazodone as a safe and effective intervention for MCI prodromal to AD.

Main Methods:

  • A randomized, double-blind, placebo-controlled, crossover trial (NCT05282550) was designed.
  • The study will enroll 100 older adults diagnosed with amnestic MCI and reporting sleep disturbances.
  • Participants will be treated with trazodone and placebo in a crossover design to assess effects on sleep and cognition.

Main Results:

  • This section details the study design and rationale, not preliminary results.
  • The trial aims to provide rigorous data on trazodone's efficacy and safety in the MCI population.
  • Expected outcomes include quantifiable improvements in slow wave sleep and cognitive function.

Conclusions:

  • Targeting sleep disturbances, particularly slow wave sleep, in MCI may offer a novel strategy to slow AD progression.
  • Trazodone shows promise as a safe agent for improving sleep in older adults.
  • Further research is needed to confirm trazodone's benefits for sleep and cognition in the prodromal stages of Alzheimer's disease.